Azenta, Inc.

NasdaqGS:AZTA Stock Report

Market Cap: US$1.5b

Azenta Past Earnings Performance

Past criteria checks 2/6

Azenta's earnings have been declining at an average annual rate of -23.5%, while the Life Sciences industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 13.9% per year. Azenta's return on equity is 1.4%, and it has net margins of 4.1%.

Key information

-23.53%

Earnings growth rate

-35.98%

EPS growth rate

Life Sciences Industry Growth21.51%
Revenue growth rate13.88%
Return on equity1.42%
Net Margin4.12%
Last Earnings Update30 Sep 2025

Recent past performance updates

Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Nov 28
Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Recent updates

Azenta: Life Science Player Coming To Life

Dec 07

Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Nov 28
Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?

Sep 12
Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?

Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Aug 07
Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Jul 24
Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
User avatar

Pharma And Biotech Outsourcing Will Shape Future Market Dynamics

Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.

Azenta: Life Science Business Failing To Come To Life

Apr 17

Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk

Apr 05
Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk

Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?

Mar 28
Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?

Azenta: Taking A Pass

Jan 27

At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?

Jan 10
At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?

A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)

Dec 20
A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

Nov 17
Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Nov 14
Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Azenta: Life Science Play Is Not Coming To Life

Sep 11

Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

Jul 19
Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?

Apr 27
Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Apr 05
Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price

Dec 28
Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price

Revenue & Expenses Breakdown

How Azenta makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:AZTA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 255942426230
30 Jun 25669-16830632
31 Mar 25669-16830932
31 Dec 24662-16630633
30 Sep 24573-2426332
30 Jun 24595-2127331
31 Mar 24616-2328433
31 Dec 23628-928934
30 Sep 23551-826432
30 Jun 23630-2130233
31 Mar 23597-2628530
31 Dec 22594-2527929
30 Sep 22555-1125128
30 Jun 22555-2826726
31 Mar 22551-2326725
31 Dec 21535-2926124
30 Sep 21514-2925222
30 Jun 21114-69183-10
31 Mar 21205-53185-2
31 Dec 20296-371839
30 Sep 20389-2619018
30 Jun 208504123259
31 Mar 208342822459
31 Dec 198121621758
30 Sep 19334-6115717
30 Jun 19741319454
31 Mar 19710718251
31 Dec 186687217049
30 Sep 186326816347
30 Jun 184883515441
31 Mar 184984714940
31 Dec 17510-214640
30 Sep 175271114140
30 Jun 176695613646
31 Mar 176344713247
31 Dec 16600-5112749
30 Sep 16434-8511644
30 Jun 16549-7312352
31 Mar 16546-7411952
31 Dec 155501211752
30 Sep 155531411452
30 Jun 15529811253
31 Mar 15502-311254

Quality Earnings: AZTA has a large one-off loss of $5.2M impacting its last 12 months of financial results to 30th September, 2025.

Growing Profit Margin: AZTA became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AZTA has become profitable over the past 5 years, growing earnings by -23.5% per year.

Accelerating Growth: AZTA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AZTA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.2%).

Return on Equity

High ROE: AZTA's Return on Equity (1.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/02 13:01
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Azenta, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christopher MuseBarclays
Brett HodessBofA Global Research
Yuan ZhiB. Riley Securities, Inc.